In a large data study, researchers discover that terazosin, a drug typically used to treat enlarged prostate, might be able to slow down neurodegeneration in Parkinson’s disease.
What are the challenges surrounding clinical trial design for genetic therapies in terms of neurodegenerative diseases? What technological advances could help bring these therapies to the clinic more quickly? Find out in our video interview with Sarah Tabrizi.
Researchers have found that the sleep history and pattern of older men and women may predict the accumulation of proteins associated with Alzheimer’s disease.
Researchers have suggested that inducing jet lag in fruit fly models of Huntington’s disease may have a neuroprotective benefit.
A team from Cleveland Clinic (OH, USA) has identified a new subtype of multiple sclerosis, termed myelocortical multiple sclerosis.
In this interview, Marika tells us about her research on tissue clearing and imaging, including her opinion on what the biggest ‘hot topic’ in neurodegeneration is.
Hannah Churchill reports on the Alzheimer’s Society Annual Conference (22–23 May, London, UK), including preventative risk factors, technology and dementia, as well as drug repurposing.
A recent study has reported that long-term consumption of caffeine has negative effects for Alzheimer’s disease, potentially worsening the neuropsychiatric symptoms in those affected by the disorder.
Rebecca Gabriele (KCL) reports on Day 2 of the ARUK Conference, including metabolism, neurodegeneration, tau, and insights into dementias from other diseases.
Scientists reveal that a new link between diminished input from dopamine-firing cells and the ability to form new memories could be crucial in detecting the earliest signs of Alzheimer’s disease.